Stoke Therapeutics/$STOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Ticker
$STOK
Sector
Primary listing
Employees
170
Headquarters
Website
STOK Metrics
BasicAdvanced
$1.8bn
-
-$2.81
1.20
-
Price and volume
Market cap
$1.8bn
Beta
1.2
52-week high
$40.22
52-week low
$9.09
Average daily volume
545k
Financial strength
Current ratio
8.986
Quick ratio
8.569
Long term debt to equity
0.251
Total debt to equity
0.867
Interest coverage (TTM)
-5,975.74%
Profitability
EBITDA (TTM)
-183.516
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-529.20%
Operating margin (TTM)
-577.46%
Effective tax rate (TTM)
0.75%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-27.24%
Return on equity (TTM)
-45.58%
Valuation
Price to revenue (TTM)
55.35
Price to book
4.62
Price to tangible book (TTM)
4.62
Price to free cash flow (TTM)
-12.022
Free cash flow yield (TTM)
-8.32%
Free cash flow per share (TTM)
-2.44
Growth
Revenue change (TTM)
-83.20%
Earnings per share change (TTM)
-419.94%
3-year revenue growth (CAGR)
30.13%
3-year earnings per share growth (CAGR)
4.42%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
STOK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs